AllianceBernstein’s Pliant Therapeutics PLRX Stock Holding History

AllianceBernstein’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-59,080	Closed	-$79.8K	–	3305
2025 Q1	$79.8K	Hold	59,080	–	–	﹤0.01%	3089
2024 Q4	$778K	Hold	59,080	–	–	﹤0.01%	2442
2024 Q3	$662K	Hold	59,080	–	–	﹤0.01%	2524
2024 Q2	$635K	Hold	59,080	–	–	﹤0.01%	2530
2024 Q1	$880K	Hold	59,080	–	–	﹤0.01%	2334
2023 Q4	$1.07M	Hold	59,080	–	–	﹤0.01%	2241
2023 Q3	$1.02M	Hold	59,080	–	–	﹤0.01%	2236
2023 Q2	$1.07M	Buy	+59,080	New	+$1.4M	﹤0.01%	2253
2023 Q1	–	Sell	-107,978	Closed	-$2.09M	–	3213
2022 Q4	$2.09M	Buy	107,978 +1,307	+1%	+$27.3K	﹤0.01%	1894
2022 Q3	$2.23M	Buy	+106,671	New	+$2.04M	﹤0.01%	1821
2022 Q2	–	Sell	-24,000	Closed	-$168K	–	3351
2022 Q1	$168K	Hold	24,000	–	–	﹤0.01%	3029
2021 Q4	$324K	Sell	24,000 -300	-1%	-$4.77K	﹤0.01%	2920
2021 Q3	$410K	Hold	24,300	–	–	﹤0.01%	2836
2021 Q2	$708K	Buy	24,300 +1,100	+5%	+$34.2K	﹤0.01%	2674
2021 Q1	$912K	Buy	+23,200	New	+$753K	﹤0.01%	2451

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

AllianceBernstein's PLRX Position: Q2 2025 in Review

AllianceBernstein sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 59,080 shares — an estimated $79.8K sold.

AllianceBernstein first reported a position in PLRX in Q1 2021 and held it in 15 quarters. The position peaked at $2.23M in Q3 2022. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

AllianceBernstein reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
AllianceBernstein sold 59,080 Pliant Therapeutics shares in Q2 2025, an estimated $79.8K.
AllianceBernstein first reported a position in Pliant Therapeutics in Q1 2021 and held it in 15 quarters.
AllianceBernstein's Pliant Therapeutics position peaked at $2.23M in Q3 2022.
114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.